Efficacy and safety of a biomarker-driven cetuximab-based treatment regimen over 3 treatment lines in mCRC patients with RAS/BRAF wild type tumors at start of first line: The CAPRI 2 GOIM trial

Efficacy and safety of a biomarker-driven cetuximab-based treatment regimen over 3 treatment lines in mCRC patients with RAS/BRAF wild type tumors at start of first line: The CAPRI 2 GOIM trial

BackgroundMonoclonal antibodies targeting EGFR such as cetuximab or panitumumab represent a major step forward in the treatment of RAS wild type (WT) metastatic colorectal cancer (mCRC). Unfortunately, primary and acquired resistance mechanisms occur, with a huge percentage of patients succumbing to...

Full description

Bibliographic Details
Main Authors: Giulia Martini, Davide Ciardiello, Stefania Napolitano, Erika Martinelli, Teresa Troiani, Tiziana Pia Latiano, Antonio Avallone, Nicola Normanno, Massimo Di Maio, Evaristo Maiello, Fortunato Ciardiello
Format: Article
Language:English
Published: Frontiers Media S.A. 2023-02-01
Series:Frontiers in Oncology
Subjects:
colorectal cancer
EGFR
liquid biopsy
biomarker
cetuximab
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2023.1069370/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2023.1069370/full

Similar Items